1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

  • October 2017
  • ID: 5251966
  • Format: PDF
  • Firstword Pharma

Summary

Table of Contents

Widespread patient access to innovative new products is being frustrated in non-US markets by Health Technology Assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in the US - but what of their status elsewhere? For example, only 35 of the 58 have been approved in the EU and of these many are tied up in HTA reviews.

The commercial impact cannot be underestimated: with no predictable outcome, companies cannot plan effectively or understand the competitive environment in which they will operate. Which companies are being impacted? What products have made the grade? When – and where – will new competitive threats emerge?

Delivering a detailed report and usable data set, this ground breaking analysis exposes the pricing, reimbursement and HTA review status of innovative drugs in Australia, Canada, France, Germany and the UK for a clear picture of the competitive landscape.

Discover on this page…
• Why this report is important to you
• Key facts about this report and data
• This report will enable you…
The deliverables: market analysis and data set
• Table of contents

Why this report is important to you

Pharma prides itself on being an innovative industry. It spends US$ billions on R&D and negotiates the regulatory regimes to gets its products approved. But overcoming the HTA hurdle is neither a standardised nor predictable process with commercially-acceptable pricing and reimbursement decisions far from guaranteed.

The burden of HTA assessment grows heavier as each national - or even sub-national - authority sets its own standards for evidence. Smaller companies and biotechs may not have either the finance or resources to engage. Knowing which companies are currently engaged and the impact on the products is critical competitive intelligence.

Key facts about this report and data
• Products: 58 innovative products covered, including ixekizumab (Eli Lilly), nusinersen (Biogen), palbociclib (Pfizer), selexipag (Actelion) and sofosbuvir/velpatasir (Gilead)
• Therapy areas: The 58 products cover 13 therapy areas – mainly oncology and neurology but also respiratory, anti-infectives, musculoskeletal and gastrointestinal
• Indications: Conditions indicated for the 58 products include cancer (various), dry eye, muscular dystrophy , hepatitis C, IBS, Parkinson’s disease and diabetes
• Companies: The products of 47 companies are covered including Actelion, Bristol-Myers Squibb, Eli Lilly, Genentech and Gilead
• Markets: Detailed information is provided for HTA status in Australia, Canada, France, Germany and the UK

This report will enable you to…
• Review the pricing, reimbursement and HTA status of each product at the national level
• Profile the therapy areas that are being targeted by innovative drugs
• Estimate likely HTA decisions using average timeframes
• Identify products that have been approved but not referred for HTA assessment
• Assess the impact of HTA systems on smaller companies and biotechs in the innovative drug space
• Profile the emerging innovative therapies in key therapy areas

Delivering market analysis and data
This report delivers two competitive analysis resources!
1. Analysis report

Rich in charts and tables, this detailed analytical report provides:
• At a glance overview of the approved drugs, therapy areas, routes of administration, company and latest sales performance
• Pricing, reimbursement and HTA policies and practices in Canada, France, Germany and the UK
• Product-level analysis providing overviews of regulatory approvals, HTA status/market launch and sales (including first half 2017 sales where available)

Delivered in Microsoft Excel™, all the data used to drive this report can be used for further analysis or to incorporate into competitive intelligence systems. For each product the data covers:
• Generic name, brand name, developer company, condition targeted and therapy area
• US FDA/EMA/Health Canada approval dates and days to approve
• HTA referral, review, decision dates and outcomes where known
• Sales performance, where relevant, in local currency and US$

Summary Contents
Overview

Approved drugs
• By therapy area
• By Route of Administration
• By company

Sales Data
• Latest Sales Revenues by Therapy Area ($m)

P&R/HTA Activity
• Canada
• France
• Germany
• UK

Drug status reports

For each of the products covered
• Product overview
• Regulatory approvals
• HTA and market launch
• Sales

Products covered
• Abaloparatide
• Alectinib
• Atezolizumab
• Avelumab
• Betrixaban
• Bezlotoxumab
• Brigatinib
• Brivaracetam
• Brodalumab
• Cerliponase Alfa
• Crisaborole
• Daclizumab
• Daratumumab
• Defibrotide
• Deflazacort
• Delafloxacin
• Dupilumab
• Durvalumab
• Edaravone
• Elbasvir/Grazoprevir
• Elotuzumab
• Eluxadoline
• Enasidenib
• Etelcalcetide
• Eteplirsen
• Glecaprevir/Pibrentasvir
• Guselkumab
• Ixazomib
• Ixekizumab
• Lenvatinib
• Lifitegrast Ophthalmic Solution
• Lixisenatide
• Midostaurin
• Naldemedine
• Necitumumab
• Neratinib Maleate
• Niraparib
• Nusinersen
• Obeticholic Acid
• Ocrelizumab
• Olaratumab
• Osimertinib
• Palbociclib
• Pimavanserin
• Plecanatide
• Reslizumab
• Ribociclib
• Rolapitant
• Rucaparib
• Safinamide
• Sarilumab
• Selexipag
• Sofosbuvir/Velpatasvir
• Sofosbuvir/Velpatasvir/Voxilaprevir
• Telotristat Ethyl
• Valbenazine
• Venetoclax

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2017

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on